Want to see INAB full AI Analyst Report?
INAB Stock Chart & Stats
$1.18
$0.03(2.20%)
At close: 4:00 PM EDT
$1.18
$0.03(2.20%)
Day’s Range― - ―
52-Week Range$0.88 - $2.73
Previous CloseN/A
Volume7.02K
Average Volume (3M)45.15K
Market Cap
$11.24M
Enterprise Value$11.67M
Total Cash (Recent Filing)$17.96M
Total Debt (Recent Filing)$2.18M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Nov 05, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding9,858,383
10 Day Avg. Volume34,234
30 Day Avg. Volume45,147
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-23.34
Enterprise Value/Ebitda-0.70
Forecast
1Y Price Target
$5.50Price Target Upside366.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.11
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated Cell-Therapy PlatformIN8bio is pursuing a specialized γδ T-cell platform spanning hematologic malignancies and solid tumors, including brain cancers. Its combination of cellular therapy and genetic engineering could support differentiated treatment development if the clinical programs validate the intended targeting and persistence benefits.
Improving Loss And Cash-Burn TrendAlthough cash generation remains negative, the reduction in free-cash-flow burn from about $24 million in 2023–2024 to $12.7 million in 2025 indicates improving spending discipline. Narrower losses and a better burn trajectory can extend operational flexibility while clinical programs advance.
Modest Financial LeverageLow debt relative to equity limits the immediate burden of interest and principal obligations compared with a highly leveraged development-stage company. This provides some balance-sheet flexibility, allowing capital allocation to remain focused on research and clinical development rather than debt service.
Bears Say
No Product RevenueIN8bio has not yet generated product revenue, so its operating model depends on advancing development programs before establishing a commercial revenue base. Until approval and commercialization occur, financial performance will remain driven by research spending, trial progress, and funding access.
Persistent Negative Cash GenerationOngoing negative operating and free cash flow means IN8bio cannot currently fund operations from internally generated cash. Continued clinical development therefore depends on external financing, which can constrain program execution and create recurring funding requirements over the next several quarters.
Capital ErosionThe substantial decline in equity and assets reflects cumulative losses and cash burn, weakening the financial base supporting the clinical pipeline. Continued capital erosion can reduce resilience, increase dependence on financing, and limit the company’s ability to absorb development setbacks.
IN8bio News
INAB FAQ
What was IN8bio’s price range in the past 12 months?
IN8bio lowest stock price was $0.88 and its highest was $2.73 in the past 12 months.
What is IN8bio’s market cap?
IN8bio’s market cap is $11.24M.
When is IN8bio’s upcoming earnings report date?
IN8bio’s upcoming earnings report date is Nov 05, 2026 which is in 14 days.
How were IN8bio’s earnings last quarter?
IN8bio released its earnings results on Aug 06, 2026. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.344 by $0.094.
Is IN8bio overvalued?
According to Wall Street analysts IN8bio’s price is currently Undervalued.
Does IN8bio pay dividends?
IN8bio does not currently pay dividends.
What is IN8bio’s EPS estimate?
IN8bio’s EPS estimate is -0.34.
How many shares outstanding does IN8bio have?
IN8bio has 9,858,383 shares outstanding.
What happened to IN8bio’s price movement after its last earnings report?
IN8bio reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.344. Following the earnings report the stock price went up 0.929%.
Which hedge fund is a major shareholder of IN8bio?
Currently, no hedge funds are holding shares in INAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IN8bio
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
INAB Stock 12 Month Forecast
Average Price Target
$5.50
▲(366.10% Upside)
Technical Analysis
Eterna Therapeutics
―
Quoin Pharmaceuticals
―
Xenetic Biosciences
―
―
Aprea Therapeutics
―
Ownership Overview
5.03% Insiders
4.49% Mutual Funds
34.48% Other Institutional Investors
55.09% Public Companies and
Individual Investors